Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"
Status:
Completed
Trial end date:
2016-05-01
Target enrollment:
Participant gender:
Summary
To evaluate different doses of "Kamada-AAT for Inhalation" on the levels of alpha
1-proteinase inhibitor and other analytes in epithelial lining fluid (ELF) and serum and to
assess the safety of the treatment in subjects with AAT Deficiency.